DNA-based biomarkers drive precision medicine, enabling breakthroughs in early detection, personalized treatment, and disease monitoring. Our amplification-free, multi-omic approaches overcome legacy limitations, delivering unmatched accuracy and insight for genomic and epigenomic discovery.
For decades, short-read technologies have shaped genomic and epigenomic research, but a new era of innovation is here. Modern native-read (direct) sequencing now achieves and often exceeds the benchmarks set by traditional methods, empowering researchers with richer data and greater confidence. Wasatch BioLabs stands at the forefront of this shift.
Direct Whole Methylome Sequencing (dWMS) provides comprehensive whole-genome methylation and sequence data in a single workflow. With flexible coverage and long-read resolution, dWMS supports gDNA applications ranging from novel variant detection to detailed methylome analysis.
Direct Methylation Sequencing (dMS) simultaneously delivers cfDNA methylation and sequence data. Optimized for fragmented DNA and equipped with flexible multiplexing, dMS provides high-resolution insights to support diverse cfDNA applications.
Explore genomic and cell-free DNA with native, single-molecule resolution, eliminating bisulfite conversion and amplification biases.
Analyze up to 27 million CpG sites across the human genome, revealing methylation patterns in complex regions.
Ensure accurate detection with optimized protocols designed for degraded or low-input samples like cfDNA.
Transform raw sequencing data into actionable insights using MethylSeqR, our user-friendly R package.
By addressing the limitations of legacy methods, Wasatch BioLabs’ approaches are transforming how genetic and methylation biomarkers are discovered, validated, and implemented. dWMS and dMS eliminate barriers like bisulfite DNA damage and amplification biases, paving the way for clinical breakthroughs.
Comprehensively capturing native DNA allows for detecting and analyzing more complex genomic and methylation biosignatures with single molecule-resolution. For example, methylation patterns from hundreds of thousands to millions of CpGs across the genome can be targeted to precisely determine DNA’s cell of origin (Figure 1).
At Wasatch BioLabs, we address limitations head-on. Our suite of native-read sequencing services eliminates location-based batch effects and preserves native DNA integrity, enabling seamless transitions from discovery to clinical application—within a single, unified ecosystem. Say goodbye to the inefficiencies of traditional workflows and accelerate your path to clinical success with Wasatch BioLabs.
From exploratory research to large-scale screenings, Wasatch BioLabs empowers biomarker discovery with unbiased sequencing solutions. Leveraging proprietary technologies like dWMS and MethylSeqR, tailored workflows, and expert bioinformatics support, we deliver actionable insights to advance your research.
Harness advanced tools like dWMS and exclusive DNA repair protocols to sequence challenging sample types, including cfDNA. Our workflows scale to meet your project’s needs, from preliminary exploration to clinical application.
Combine tailored workflows with advanced analysis tools for methylation, DNA sequence, and structural variant data, delivering impactful, publication-ready results.
Simplify methylation analysis with MethylSeqR, our user-friendly R package that transforms raw nanopore data into actionable insights faster than ever.
Work with native-read sequencing experts with decades of experience in genomics, epigenomics, and bioinformatics to guide your project from discovery to clinical success.
